CHNXF (ChitogenX) Other Operating Expense: $0.00 Mil (TTM As of Oct. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is ChitogenX Other Operating Expense?

ChitogenX CHNXF Other Operating Expense is $0.00 Mil as of Oct. 2024.

ChitogenX's Other Operating Expense for the three months ended in Oct. 2024 was $0.00 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Oct. 2024 was $0.00 Mil.

ChitogenX's quarterly Other Operating Expense stayed the same from Apr. 2024 ($0.00 Mil) to Jul. 2024 ($0.00 Mil) but then increased from Jul. 2024 ($0.00 Mil) to Oct. 2024 ($0.00 Mil).

ChitogenX's annual Other Operating Expense stayed the same from Jan. 2022 ($0.00 Mil) to Jan. 2023 ($0.00 Mil) but then declined from Jan. 2023 ($0.00 Mil) to Jan. 2024 ($-0.00 Mil).

ChitogenX Other Operating Expense Historical Data

* Premium members only.

The historical data trend for ChitogenX's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ChitogenX Other Operating Expense Chart

ChitogenX Annual Data
Trend Jan16 Jan17 Jan18 Jan19 Jan20 Jan21 Jan22 Jan23 Jan24
Other Operating Expense
Get a 7-Day Free Trial Premium Member Only 0.02 0.01 0.00 0.00 -0.00

ChitogenX Quarterly Data
Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ChitogenX Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Oct. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Other Operating Expense of $0.00 Mil mean?
ChitogenX (CHNXF) has a Other Operating Expense of $0.00 Mil as of Oct. 2024. Other operating expenses that a company records on its income statement. View historical data on ChitogenX and its competitors.
Is ChitogenX's Other Operating Expense too high?
ChitogenX's current Other Operating Expense is $0.00 Mil.
How does ChitogenX's Other Operating Expense compare to SCPX and LADX?
ChitogenX's Other Operating Expense of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Biotechnology company?
A good Other Operating Expense depends on the Biotechnology industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on ChitogenX and its competitors. ChitogenX's current Other Operating Expense is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ChitogenX stock overvalued right now?
ChitogenX (CHNXF) has a current Other Operating Expense of $0.00 Mil. The current Other Operating Expense is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For ChitogenX (CHNXF), the current Other Operating Expense is $0.00 Mil as of Oct. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ChitogenX Business Description

Address 16667 Hymus Boulevard, Kirkland, Montreal, QC, CAN, H9H 4R9
ChitogenX Inc is a clinical-stage biotech company. It operates in one segment, which is the development of novel therapeutic soft tissue repair technologies.